Please login to the form below

Not currently logged in
Email:
Password:

UCB recruits Yale professor to expand New Medicines team

Marc Laruelle joins the Belgium-based company as head of CNS

UCB has appointed a fourth member of its New Medicines leadership team, recruiting Yale University professor of psychiatry Marc Laruelle as vice president, head of CNS.

The Belgium pharma company has been expanding its research and early development team of late, and Laruelle's appointment follows those of GlaxoSmithKline's Mark Bodmer and Genentech's Peter Theil.

Laruelle joins UCB from Yale University, where he held the position of Professor of Psychiatry from 2010 and prior to this served at GlaxoSmithKline as head of the discovery performance unit for schizophrenia and cognitive disorders.

UCB's New Medicines unit is based around two European research hubs - Braine-l'Alleud in Belgium for central nervous system (CNS) diseases and Slough for immunological disordersl. Their work covers discovery research through to clinical proof of concept.

Laruelle joins UCB's other recent new recruits to New Medicines - head of global exploratory development Duncan McHale , head of non-clinical development Peter Theil and head of immunology Mark Bodmer.

12th March 2012

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Blue Latitude Health

Blue Latitude Health is a creative marketing consultancy. Founded in 2003, our combination of heritage, approach and capability gives us...

Latest intelligence

Genomics integration: can the NHS rise to the challenge?
Experts gather to discuss the UK’s genomic landscape...
London
“Brexit has been a catalyst for UK clinical research... it’s turbocharged change”
The UK clinical trials environment has been transformed in recent years – but can it really buck Brexit’s risks and uncertainties?...
The Future of Pharma sales: fast forward to 2029
Change is inevitable, and necessary, for growth in business....

Infographics